. Author manuscript; available in PMC: 2019 Aug 7.

Published in final edited form as: Genet Med. 2019 Jan 23;21(8):1842–1850. doi: 10.1038/s41436-018-0431-8

Table 2.

CYP2D6 Phenotype Based on CYP2D6 Genotype versus Genotype plus CYP2D6 Inhibitor Use (n=343)^a

CYP2D6 Phenotype	Genotype	Genotype + drug interactions^c
PM	18 (5.3)	66 (19.2)
IM	17 (5.0)	55 (16.0)
NM	294 (85.7)	208 (60.6)
Other^b	14 (4.1)	14 (4.1)

No. (%)

Data for two participants in the usual care arm are not shown as they refused genotyping.

Other consists of indeterminate genotypes (n=4) and CYP2D6 duplication that resulted in a ranged phenotype (e.g. IM-NM, NM-UM) because of the inability to determine which allele was duplicated or multiplicated and the number of allele copies (n=10).

91 patients had phenoconversion (12 were taking two moderate or strong inhibitors): 43 converted from NM to IM; 43 converted from NM to PM; and 5 converted from IM to PM.

PM, poor metabolizer; IM, intermediate metabolizer; NM, normal metabolizer; UM, ultra-rapid metabolizer